1.240USD-1.59%Mkt Cap: 65.06M USDP/E: —Last update: 2026-05-26
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezata…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap65.06M USD
Enterprise Value-24.99M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.74M USD
Revenue/Share—
Last Price1.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees54
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.17
PEG—
EV/EBITDA0.30
EV/Revenue—
P/S—
P/B0.65
EPS (TTM)-1.48
EPS (Forward)-1.09
52W Range
0.850038% of range1.880
52W High1.880 USD
52W Low0.8500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-74.24%
ROA-66.70%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-73.58M USD
CapEx (TTM)29.00K USD
FCF Margin—
FCF Yield-72.34%
Net Debt-93.26M USD
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.01
Current Ratio11.14
Quick Ratio10.88
Book Value/Sh1.963 USD
Cash/Share1.754 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.333 USD
Target Range4.000 USD – 5.000 USD
# Analysts3
Ownership
Shares Out.53.33M
Float43.14M
Insiders3.35%
Institutions69.52%
Short Interest
Short Ratio6.5d
Short % Float5.11%
Short % Out.4.94%
Shares Short2.63M
Short (prev mo.)1.56M
Technical
SMA 501.388 (-10.6%)
SMA 2001.339 (-7.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)417.18K
Avg Vol (10d)513.71K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—